文献速递糖尿病

阿卡波糖对冠心病合并糖耐量受损患者糖尿病发病及血糖正常化的影响:ACE试验的启示

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
PubMed 文献 · Diabetes Care · 2020-07-08

基于中国ACE试验6522例糖耐量受损合并冠心病患者,随机接受阿卡波糖或安慰剂,每四个月检测空腹血糖、每年行口服葡萄糖耐量试验。阿卡波糖组糖尿病发病率低于安慰剂组(每100人年3.2 vs 3.8,率比0.82 [95%CI 0.71,0.94],P=0.005),且血糖正常化率更高(每100人年16.3 vs 14.1,率比1.16 [95%CI 1.08,1.25],P<0.0001)。结论认为阿卡波糖减少糖尿病发病并促进血糖正常化。

要点

  • 阿卡波糖组糖尿病发病率为每100人年3.2,安慰剂组为3.8,率比0.82(95%CI 0.71,0.94),P=0.005。
  • 阿卡波糖组血糖正常化率为每100人年16.3,安慰剂组为14.1,率比1.16(95%CI 1.08,1.25),P<0.0001。
  • 未使用ACEI或ARB者中阿卡波糖对血糖正常化的效应更大(率比1.36 [95%CI 1.21,1.53],交互作用P=0.0006)。

核心结论

  • 在中国糖耐量受损合并冠心病患者中,阿卡波糖降低糖尿病发病率并促进血糖正常化。

研究设计与样本

  • ACE试验随机对照研究,6522例中国糖耐量受损合并冠心病患者随机分配至阿卡波糖或安慰剂组,每四个月检测空腹血糖,每年行口服葡萄糖耐量试验。

主要发现

  • 阿卡波糖组糖尿病发病率为每100人年3.2,安慰剂组为每100人年3.8,率比0.82(95%CI 0.71,0.94),P=0.005。
  • 阿卡波糖组血糖正常化率为每100人年16.3,安慰剂组为每100人年14.1,率比1.16(95%CI 1.08,1.25),P<0.0001。
  • 未使用ACEI或ARB者中阿卡波糖对血糖正常化的效应更大(率比1.36 [95%CI 1.21,1.53],交互作用P=0.0006)。
  • 阿卡波糖组与安慰剂组维持血糖正常化状态的可能性无显著差异(P=0.41)。

关键数值与推荐

  • 糖尿病定义为连续两次空腹血糖≥7 mmol/L或2小时血浆葡萄糖≥11.1 mmol/L(服药期间)或盲法裁定确认。
  • 血糖正常化定义为空腹血糖<6.1 mmol/L且2小时血浆葡萄糖<7.8 mmol/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined the impact of acarbose, an α-glucosidase inhibitor, on incident diabetes and regression to normoglycemia in 6,522 Acarbose Cardiovascular Evaluation (ACE) trial participants in China who had impaired glucose tolerance (IGT) and coronary heart disease (CHD). RESEARCH DESIGN AND METHODS: Participants were randomly assigned to acarbose or placebo and followed with four monthly fasting plasma glucose (FPG) tests and annual oral glucose tolerance tests. Incident diabetes was defined as two successive diagnostic FPG levels ≥7 mmol/L or 2-h plasma glucose (PG) levels ≥11.1 mmol/L while taking study medication or a masked adjudicated confirmation of this diagnosis. Regression to normoglycemia was defined as FPG <6.1 mmol/L and 2-h PG <7.8 mmol/L. Intention-to-treat and on-treatment analyses were conducted using Poisson regression models, overall and for subgroups (age, sex, CHD type, HbA1c, FPG, 2-h PG, BMI, estimated glomerular filtration rate, for IGT alone, for IGT + impaired fasting glucose, and for use of thiazides, ACE inhibitors [ACEis]/angiotensin receptor blockers [ARBs], β-blockers, calcium channel blockers, or statins). RESULTS: Incident diabetes was less frequent with acarbose compared with placebo (3.2 and 3.8 per 100 person-years, respectively; rate ratio 0.82 [95% CI 0.71, 0.94], P = 0.005), with no evidence of differential effects within the predefined subgroups after accounting for multiple testing. Regression to normoglycemia occurred more frequently in those randomized to acarbose compared with placebo (16.3 and 14.1 per 100 person-years, respectively; 1.16 [1.08, 1.25], P < 0.0001). This effect was greater in participants not taking an ACEi or ARB (1.36 [1.21, 1.53], P interaction = 0.0006). The likelihood of remaining in normoglycemic regression did not differ between the acarbose and placebo groups (P = 0.41). CONCLUSIONS: Acarbose reduced the incidence of diabetes and promoted regression to normoglycemia in Chinese people with IGT and CHD.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Gerstein HC, Coleman RL, Scott CAB, et al. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes Care. 2020. PMID: 32641379. doi:10.2337/dc19-2046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。